作者
O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, N Abdallah, A Abdelaziz, M Abdelfattah, B Abdelqader, A Abdul, B Abdul, S Abdul, A Abdul Rasheed, A Abdulakeem, R Abdul-Kadir, A Abdullah, A Abdulmumeen, R Abdul-Raheem, N Abdulshukkoor, K Abdusamad, Y Abed El Khaleq, M Abedalla, A Abeer Ul Amna, L Abel, K Abernethy, M Abeywickrema, C Abhinaya, A Abidin, A Aboaba, A Aboagye-Odei, C Aboah, H Aboelela, H Abo-Leyah, K Abouelela, A Abou-Haggar, M Abouibrahim, A Abousamra, M Abouzaid, M Abraham, T Abraham, A Abraheem, J Abrams, R Abrams, HJ Abu, A Abu-Arafeh, SM Abubacker, A Abung, Y Abusamra, Y Aceampong, A Achara, D Acharya, F Acheampong, P Acheampong, S Acheampong, J Acheson, S Achieng, A Acosta, R Acquah, C Acton, J Adabie-Ankrah, P Adair, AS Adam, F Adam, M Adam, H Adamali, M Adamczyk, C Adams, D Adams, K Adams, L Adams, N Adams, R Adams, T Adams, L Adamu-Ikeme, K Adatia, K Adcock, L Addai-Boampong, A Addo, O Adeagbo, A Adebiyi, O Adedeji, Y Adegeye, K Adegoke, V Adell, S Adenwalla, FW Adeoye, OA Adesemoye, EO Adewunmi, A Adeyanju, J Adeyemi, T Adeyemo, B Adhikari, SA Adhikari, R Adhikary, A Aditya, P Adjepong, G Adkins, A Adnan, M Adriaanse, J Aeron-Thomas, D Affleck, C Afnan, M Afridi, P Afrim, FA Afriyie, ZA Aftab, A Afum-Adjei Awuah, M Agarwal, PN Agasiya, R Agbeko, C Agbo, S Aggarwal, A Aghababaie, L Aguilar Jimenez, JA Agyekum, K Agyen, EK Ahadome, S Ahamed Sadiq, MH Ahammed Nazeer, M Ahmad, S Ahmad, A Ahmed, BAR Ahmed, B Ahmed, F Ahmed, H Ahmed, I Ahmed, K Ahmed, L Ahmed, M Ahmed, MC Ahmed, MS Ahmed, N Ahmed, O Ahmed, RA Ahmed, R Ahmed, S Ahmed, SG Ahmed, SH Ahmed, R Ahmed Ali, B Ahmed Mohamud, S Ahmer, A Ahonia, C Aidoo, C Aiken, D Ail
发表日期
2023/12/1
期刊
The Lancet Diabetes & Endocrinology
卷号
11
期号
12
页码范围
905-914
出版商
Elsevier
简介
Background
Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.
Methods
In the randomised, controlled, open-label RECOVERY trial, several possible treatments are compared with usual care in patients hospitalised with COVID-19. In this analysis, we assess eligible and consenting adults who were randomly allocated in a 1: 1 ratio to either usual standard of care alone or usual standard of care plus oral empagliflozin 10 mg once daily for 28 days or until discharge (whichever came first) using web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28-day mortality; secondary outcomes were duration of hospitalisation and (among participants not on invasive mechanical …
学术搜索中的文章
O Abani, A Abbas, F Abbas, J Abbas, K Abbas… - The Lancet Diabetes & Endocrinology, 2023